High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer

Histopathology

Volumn 61, Issue 3, 2012, Pages 409-416

  Klauschen, Frederick ^a   von Winterfeld, Moritz ^a   Stenzinger, Albrecht ^b   Sinn, Bruno V ^a   Budczies, Jan ^a   Kamphues, Carsten ^a   Bahra, Marcus ^a   Wittschieber, Daniel ^a   Weichert, Wilco ^b   Striefler, Jana ^a   Riess, Hanno ^a   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Immunohistochemistry; Pancreatic cancer; Poly (ADP ribose) polymerase; Prognostic biomarker

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CELL NUCLEUS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS SURGERY; PATHOPHYSIOLOGY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TISSUE SECTION;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865393927     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04225.x     Document Type: Article

References (37)

1. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004; 350; 1200-1210.
2. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J. Surg. 2003; 27; 324-329.
3. Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. J. Pancreas 2008; 9; 99-132.
4. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br. J. Cancer 2011; 104; 1440-1451.
5. Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br. J. Surg. 2011; 98; 1041-1055.
6. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26; 882-893.
7. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006; 7; 517-528.
8. Bouchard VJ, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Exp. Hematol. 2003; 31; 446-454.
9. Kraus WL, Lis JT. PARP goes transcription. Cell 2003; 113; 677-683.
10. Nicoletti VG, Stella AM. Role of PARP under stress conditions: cell death or protection? Neurochem. Res. 2003; 28; 187-194.
11. Caiafa P, Guastafierro T, Zampieri M. Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J. 2009; 23; 672-678.
12. von Minckwitz G, Mueller BM, Loibl S et al. Cytoplasmic PARP expression is predictive and prognostic in breast cancer patients treated by neoadjuvant chemotherapy. J. Clin. Oncol. 2011; 29; 2150-2157.
13. Telli ML, Ford JM. PARP inhibitors in breast cancer. Clin. Adv. Hematol. Oncol. 2010; 8; 629-635.
14. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010; 10; 293-301.
15. Penning TD. Small-molecule PARP modulators-current status and future therapeutic potential. Curr. Opin. Drug. Discov. Devel. 2010; 13; 577-586.
16. Boss DS, Beijnen JH, Schellens JH. Inducing synthetic lethality using PARP inhibitors. Curr. Clin. Pharmacol. 2010; 5; 192-195.
17. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 2008; 26; 3785-3790.
18. Turner NC, Lord CJ, Iorns E et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008; 27; 1368-1377.
19. Sterling JA, Wu L, Banerji SS. PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines. Anticancer Res. 2006; 26; 1893-1901.
20. Ogino H, Nozaki T, Gunji A et al. Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genomics 2007; 8; 41.
21. Shibata A, Maeda D, Ogino H et al. Role of Parp-1 in suppressing spontaneous deletion mutation in the liver and brain of mice at adolescence and advanced age. Mutat. Res. 2009; 664; 20-27.
22. Martin-Oliva D, O'Valle F, Munoz-Gamez JA et al. Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia. Oncogene 2004; 23; 5275-5283.
23. Mazzon E, Genovese T, Di Paola R et al. Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein. Eur. J. Pharmacol. 2006; 549; 149-156.
24. Mota R, Sánchez-Bueno F, Berenguer-Pina JJ, Hernandez-Espinosa D, Parrilla P, Yelamos J. Therapeutic treatment with poly(ADP-ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury. Br. J. Pharmacol. 2007; 151; 998-1005.
25. Mota RA, Sánchez-Bueno F, Saenz L et al. Inhibition of poly(ADP-ribose) polymerase attenuates the severity of acute pancreatitis and associated lung injury. Lab. Invest. 2005; 85; 1250-1262.
26. Yasar M, Uysal B, Kaldirim U et al. Poly(ADP-ribose) polymerase inhibition modulates experimental acute necrotizing pancreatitis-induced oxidative stress, bacterial translocation and neopterin concentrations in rats. Exp. Biol. Med. (Maywood) 2010; 235; 1126-1133.
27. Takasawa S, Okamoto H. Pancreatic beta-cell death, regeneration and insulin secretion: roles of poly(ADP-ribose) polymerase and cyclic ADP-ribose. Int. J. Exp. Diabetes Res. 2002; 3; 79-96.
28. Pieper AA, Brat DJ, Krug DK et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc. Natl Acad. Sci. USA 1999; 96; 3059-3064.
29. Charron MJ, Bonner-Weir S. Implicating PARP and NAD+ depletion in type I diabetes. Nat. Med. 1999; 5; 269-270.
30. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8; 138-140.
31. Friedberg EC. DNA damage and repair. Nature 2003; 421; 436-440.
32. Sieber O, Heinimann K, Tomlinson I. Genomic stability and tumorigenesis. Semin. Cancer Biol. 2005; 15; 61-66.
33. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 2010; 11; 220-228.
34. Oei SL, Keil C, Ziegler M. Poly(ADP-ribosylation) and genomic stability. Biochem. Cell Biol. 2005; 83; 263-269.
35. Tell G, Wilson DM 3rd. Targeting DNA repair proteins for cancer treatment. Cell. Mol. Life Sci. 2010; 67; 3569-3572.
36. Carson DA, Carrera CJ, Wasson DB, Yamanaka H. Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes. Adv. Enzyme Regul. 1988; 27; 395-404.
37. Frizzell KM, Gamble MJ, Berrocal JG et al. Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells. J. Biol. Chem. 2009; 284; 33926-33938.